Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this drugmaker have returned +0.

Those were in great demand at the beginning of the pandemic, and generated gobs of money for Pfizer. Demand has waned, though, and the stock has stopped soaring. It has averaged annual gains of 6.5% over the past 15 years, and average annual losses of 8.8% over the past three years. It's up 10.4% year to date as I write this.

Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.

Pfizer (NYSE:PFE) received its first Chinese approval for obesity drug Severwin, opening access to a major new treatment category. The Severwin approval follows recent licensing deals that expanded Pfizer's presence in metabolic disease therapies.

Pfizer's dividend yield is a lofty 6.2%. That's well above the 1.1% yield offered by the S&P 500 index and the 1.7% yield of the average pharmaceutical stock. And the company recently provided longer-term financial guidance that included a commitment to maintaining the dividend. Image source: Getty Images.

It has been about a month since the last earnings report for Pfizer (PFE). Shares have lost about 0.6% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release,

Eli Lilly is making headlines in the pharmaceutical sector, but it's a very expensive stock.

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company has made investments and acquisitions to strengthen its ...

Pfizer Inc. (NYSE:PFE) is one of the best cheap stocks under $50 to buy right now. Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. announced on February 27 positive results from the Phase 3 EV-304 clinical trial for PADCEVTM,

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Dividend Stocks to Invest in Under $50. On March 2, Argus upgraded Pfizer Inc. (NYSE:PFE) to Buy from Hold. The firm set a $35 price target on the stock.

Pfizer beat on 2025 sales and beat on earnings -- but still delivered a loss. Pfizer reaffirmed 2026 sales and earnings guidance for under $3 per share. 10 stocks we like better than Pfizer › Pfizer (NYSE: PFE) stock gave up 3.3% through 10:50 a.m. ET ...